SNNUF News and Press, Smith & Nephew Plc Ord From 05/14/23

2023-05-14 01:05:59 ET Summary Smith & Nephew has caught a 21% bid in the past 6 months despite no major fundamental changes. Long-term data analysis reveals the company's difficulty in turning capital investments into additional market valuation. Shares look to be fairly ...

Summary Smith & Nephew saw flat top-line growth, declines in earnings and CFFO relative to FY21. Management has instilled a new 12-point plan in order to drive performance from FY23 onwards. It is now a matter of execution, and we rate SNN a hold at 24x earnings, in-line with th...

Summary Smith & Nephew plc's fourth quarter results were mixed; Ortho is still lagging its rivals, but Sports Medicine & ENT and Advanced Wound Care outperformed. The company has the technology to be more competitive in ortho and gain share in major joints and extremities, but w...

Smith & Nephew plc (SNN) Q4 2022 Earnings Conference Call February 21, 2023, 03:30 AM ET Company Participants Deepak Nath - CEO Anne-Francoise Nesmes - CFO Conference Call Participants Jack Reynolds-Clark - RBC Hassan Al-Wakeel - Barclays Kyle Rose ...

Summary The Palm Valley Capital Fund invests in small cap stocks. While our Fund is new, its underlying absolute return-based investment strategy is not. We have practiced the same strategy throughout our careers in investment management. We do not believe U.S. stocks are pricing in an ...

Summary The Palm Valley Capital Fund invests in small cap stocks. While our Fund is new, its underlying absolute return-based investment strategy is not. We have practiced the same strategy throughout our careers in investment management. The combination of falling stock prices an...

Summary Smith & Nephew extends its downside in September and the question now turns to what value might be on offer. On closer inspection, there's been good reasoning behind the market's pricing of SNN this year. With contracting growth and forex headwinds still plaguing e...

Smith & Nephew plc (SNN) Q2 2022 Results Conference Call July 28, 2022 03:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America ...

Bioventus' diversified portfolio insulates the company from peers and enables it to innovate around its core offering. The company holds market-leading positions in several complex pain segments, offering non-invasive treatment solutions. There are high earnings and FCF growth pot...

Zimmer Biomet has greatly underperformed the S&P 500 as well as the iShares IHI, been stagnant over the past 5 years. The street consensus gives some hope for the projected growth with an estimated 28.67% FCF and 7.19% EBIT CAGR over the next 5 years. Zimmer Biomet carries not...